Saturday 17 October 2026
Export CNTB’s income statement to Excel — free account
Connect Biopharma Holdings Limited Sponsored ADR
CNTB Healthcare Biotechnology
Connect Biopharma Holdings Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $64,000.00, down 99.8% from fiscal 2024. In the quarter to June 2026, revenue grew 296.6%, EPS fell 17.4%, free cash flow fell 23.5% and total debt fell 61.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.91
0.00
0.00%
Follow CNTB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | — | 0.00 | 0.00 |
P/S ratio |
42.47 | — | 159.13 | 49.87 | |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | |
P/Operating CF |
(4.83) | — | (9.26) | (9.40) | |
P/B ratio |
1.52 | — | 3.48 | 5.57 | |
Price to Tangible BV |
1.52 | — | 3.48 | 5.58 | |
EV/Sales |
15.04 | — | 109.99 | 39.45 | |
EV/EBITDA |
0.00 | — | 0.00 | 0.00 | |
EV/Operating CF |
(0.70) | — | (1.79) | (1.95) | |
EV/FCF |
(0.69) | — | (1.78) | (1.94) | |
Quick Ratio |
5.48 | 3.74 | 3.23 | 2.37 | |
Current Ratio |
5.48 | 3.74 | 3.23 | 2.37 | |
Net Debt/EBITDA |
3.11 | 2.87 | 2.35 | 1.79 | |
Debt/Assets |
0.66% | 0.66% | 0.48% | 0.47% | |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.02 | 0.00 | 0.01 | 0.05 | |
Operating CF/Net income |
1.01 | 0.74 | 0.83 | 0.92 | |
Capex/Depreciation |
(0.19) | (0.09) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
69,437.50% | 0.00% | 8,893.49% | 587.90% | |
Selling, General and Administrative Expense of Revenue |
41,143.75% | 0.00% | 2,808.28% | 148.09% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5,725.00% | 0.00% | 709.47% | 45.56% | |
Graham Net Nets |
0.60 | — | 0.25 | 0.15 | |
Graham Number |
0.00 | — | 0.00 | 0.00 | |
Earnings Yield |
(59.03%) | — | (43.89%) | (50.00%) | |
Free Cash Flow Yield |
(51.12%) | — | (38.94%) | (40.77%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.04 | |
Operating CF per Share |
(0.31) | (0.20) | (0.28) | (0.25) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.31) | (0.20) | (0.28) | (0.25) | |
Cash per Share |
0.98 | 0.80 | 0.81 | 0.50 | |
Shareholders Equity per Share |
0.99 | 0.75 | 0.75 | 0.43 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.99 | 0.75 | 0.75 | 0.43 | |
Free Cash Flow |
(17.44) | (11.27) | (16.00) | (15.92) | |
Working Capital |
51.17 | 37.32 | 37.98 | 22.32 | |
Capital Expenditures |
(0.03) | (0.02) | — | — | |
Net Current Asset Value |
50.61 | 36.83 | 37.58 | 22.01 | |
EV/EBIT |
0.00 | — | 0.00 | 0.00 | |
Capex to Sales |
2.13 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.99 | 4.92 | 6.37 | 6.56 | |
Average Payables |
3.85 | 1.15 | 2.56 | 2.16 | |
Average Assets |
93.97 | 78.68 | 76.38 | 63.10 | |
Average Common Equity |
82.93 | 67.07 | 62.76 | 49.10 |
Columns are period end dates